IDEAYA Biosciences, (IDYA) Institutional Ownership
Track institutional investors, ownership changes, and 13F filings.
Ownership Summary
Total Institutions
206
Total Shares Held
91.94M
Total Value
$2.36B
Institutional Holding %
106.67%
Ownership Distribution
Top 5 Holders
Top Institutional Holders (as of Dec 31, 2024)
| Institution | Shares | Ownership % | Value |
|---|---|---|---|
| FMR | 12.96M | 15.04% | $333.15M |
| BlackRock | 8.38M | 9.72% | $215.29M |
| JANUS HENDERSON | 5.86M | 6.80% | $150.61M |
| VANGUARD | 5.08M | 5.89% | $130.51M |
| FEDERATED HERMES | 5.06M | 5.87% | $130.13M |
| PRICE T ROWE | 3.87M | 4.49% | $99.38M |
| STATE STREET | 3.32M | 3.85% | $85.35M |
| LOGOS GLOBAL | 3.00M | 3.48% | $77.10M |
| DEERFIELD COMPANY (SERIES C) | 2.74M | 3.17% | $70.32M |
| CAPITAL RESEARCH GLOBAL INVESTORS | 2.57M | 2.98% | $65.94M |
Recent Insider Trading
| Insider | Title | Transaction | Shares | Value | Date |
|---|---|---|---|---|---|
| Beaupre Darrin | Chief Medical Officer | A-Award | 185.00K | $3.74M | Feb 27, 2025 |
| Dorman Stuart | Chief Commercial Officer | A-Award | 15.00K | $303.60K | Feb 27, 2025 |
| Ruiz Briseno Andres | See Remarks | A-Award | 75.00K | $1.52M | Feb 27, 2025 |
| White Michael Anthony | Chief Scientific Officer | A-Award | 185.00K | $3.74M | Feb 27, 2025 |
| Snyder Douglas B. | Svp, General Counsel | A-Award | 33.00K | $667.92K | Feb 27, 2025 |
| Hata Yujiro S | Director, President And Ceo | A-Award | 600.00K | $12.14M | Feb 27, 2025 |
| Hata Yujiro S | Director, President And Ceo | M-Exempt | 12.81K | $250.01K | Feb 18, 2025 |
| Hata Yujiro S | Director, President And Ceo | M-Exempt | 12.81K | $250.01K | Feb 18, 2025 |
| Dorman Stuart | Chief Commercial Officer | 170.00K | $4.67M | Dec 11, 2024 | |
| Snyder Douglas B. | Svp, General Counsel | A-Award | 140.00K | $4.27M | Sep 26, 2024 |
Recent Position Changes
| Institution | Shares Changed | % Change | Date |
|---|---|---|---|
| MORGAN STANLEY | +1.19M | +331.20% | Feb 14, 2025 |
| LOGOS GLOBAL | +900.00K | +42.86% | Feb 14, 2025 |
| GOLDMANCHS | +888.95K | +102.27% | Feb 11, 2025 |
| CITADEL | +784.45K | +74.54% | Feb 14, 2025 |
| BlackRock | +696.12K | +9.06% | Feb 07, 2025 |
| JANUS HENDERSON | +695.26K | +13.47% | Feb 14, 2025 |
| SOFINNOVA | -680.37K | -38.89% | Feb 14, 2025 |
| NORGES BANK | +520.81K | +100.00% | Feb 12, 2025 |
| EVENTIDE ASSET | +436.84K | +130.40% | Feb 14, 2025 |
| BIOIMPACT | +414.04K | +100.00% | Feb 14, 2025 |
Recent Ownership Filings
4
Form 4 - Statement of changes in beneficial ownership of securities
Feb 28, 2025
4
Form 4 - Statement of changes in beneficial ownership of securities
Feb 28, 2025
4
Form 4 - Statement of changes in beneficial ownership of securities
Feb 28, 2025
4
Form 4 - Statement of changes in beneficial ownership of securities
Feb 28, 2025
4
Form 4 - Statement of changes in beneficial ownership of securities
Feb 28, 2025
4
Form 4 - Statement of changes in beneficial ownership of securities
Feb 28, 2025
4
Form 4 - Statement of changes in beneficial ownership of securities
Feb 19, 2025
SC 13G/A
Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Nov 14, 2024
SC 13G/A
Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Nov 14, 2024
SC 13G/A
Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Nov 14, 2024
SC 13G/A
Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Nov 12, 2024
4
Form 4 - Statement of changes in beneficial ownership of securities
Sep 27, 2024
144
Form 144 - Report of proposed sale of securities
Aug 26, 2024
4
Form 4 - Statement of changes in beneficial ownership of securities
Jun 27, 2024
4
Form 4 - Statement of changes in beneficial ownership of securities
May 31, 2024
4
Form 4 - Statement of changes in beneficial ownership of securities
May 31, 2024
4
Form 4 - Statement of changes in beneficial ownership of securities
May 31, 2024
4
Form 4 - Statement of changes in beneficial ownership of securities
May 31, 2024
Related Metrics
Explore detailed financial metrics and analysis for IDYA.